Video

Dr. Stone Discusses Monitoring MRD in AML

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease in acute myeloid leukemia.

Richard M. Stone, MD, director of the Adult Leukemia Program, Dana-Farber Cancer Institute, and professor of medicine, Harvard Medical School, discusses monitoring minimal residual disease (MRD) in acute myeloid leukemia (AML).

One of the most important questions in AML is the clinical relevance of monitoring MRD, says Stone.

Historically, AML therapy success has been measured based on morphologic assessment of the bone marrow. If there are less than 5% blasts in the marrow, the patient is deemed to be in remission—but researchers now want a way to measure the depth of that remission.

Related Videos
Minoo Battiwalla, MD, MS
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Benjamin P. Levy, MD, with Kristie Kahl and Andrew Svonavec
Francine Foss, MD